Strategic Partnerships Jellagen has actively pursued collaborations with industry players and research institutions, including a strategic partnership with Royal Biologics and a collaboration with Alta Bioscience. Sales opportunities exist in co-development, licensing, and joint research programs to accelerate Type Zero applications and expand market reach.

Board-Level Expansion Recent appointment of Salvatore Leo as strategic commercialization lead and board member signals a sharpened go-to-market focus for the Type Zero product launch. This presents a clear entry point for SMBs and larger partners seeking to align with a prepared leadership team.

Regenerative Medicine Focus Product centers on jellyfish collagen Type 0 as a foundational material for regenerative medicine across multiple indications. There is demand potential from biotech firms, academic labs, and contract research organizations pursuing advanced biomaterials and tissue engineering applications.

Research & Validation Active collaborations and publications with NPL and materials science outlets validate the technology. Sales plays can leverage case studies, regulatory-ready data, and published results to build credibility with pharma, medtech, and academic buyers.

Funding & Growth History of notable funding rounds and a recent Series A prominence demonstrate capital readiness and investor confidence. This supports scalable partnerships, pilot programs, and regional expansion into UK and international markets, especially for contract manufacturing and bespoke analysis services.